SWIFT PRIME Acute Ischemic Stroke Study

Update: This study is on hold until further notice, please call (561) 882-9100 for more information.

St. Mary's Medical Center Participates in SWIFT PRIME Acute Ischemic Stroke Study

New Clinical Trial Represents One of the Largest Global Studies to Examine the Effectiveness of Advanced Mechanical Treatment in Stroke Care

St. Mary’s Medical Center doctors are joining an international clinical study, SWIFT PRIME, to examine the adjunctive use of mechanical thrombectomy during the early stages of acute ischemic stroke onset.

The randomized controlled trial may enroll up to 800 patients across 60 centers globally and will examine acute ischemic stroke patients treated with either intravenous tissue plasminogen activator (IV tPA) alone or IV tPA in combination with Covidien’s Solitaire™ FR Revascularization Device, an overlapping stent-based technology that provides substantially improved clinical outcomes to the previous generation of devices. The study will also include an extensive health economics analysis.

"Part of our responsibility as a Comprehensive Stroke Center is to do research and educate," said Dr. Ali Malek, the trial’s principal investigator and Medical Director of the Comprehensive Stroke Center at St. Mary’s Medical Center. "Participating in this study allows us to be proactive in searching for the best way to treat acute ischemic stroke patients."

Acute ischemic stroke occurs when a clot in a blood vessel blocks blood supply to the brain. According to the American Heart Association, acute ischemic stroke is the leading cause of disability and the fourth most common cause of death in the United States.

"We are excited to be part of this important initiative and combine our research strengths to improve the health of citizens all over the world," said CEO Davide Carbone. "Collaborative research at St. Mary’s Medical Center is part of our efforts to provide the highest level of care to the members of our community."

The Solitaire FR device that will be used in the trial received U.S. FDA 510(k) marketing clearance in 2012 and CE Mark approval in 2009.